Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohnâs disease, and psoriasis. Source
No articles found.
Cancer is one of the most difficult diseases to treat. It is constantly changing, ...
Cancer is one of the most difficult diseases to...
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device compan...
Cardiovascular Systems, Inc., based in St. Paul...
UNITY Biotechnology is developing therapeutics to extend human healthspan by slowi...
UNITY Biotechnology is developing therapeutics ...
Tocagen is a clinical-stage, cancer-selective gene therapy company developing firs...
Tocagen is a clinical-stage, cancer-selective g...
uniQure is delivering on the promise of gene therapy -- single treatments with pot...
uniQure is delivering on the promise of gene th...
We're developing Vipax, the world's first portable, shelf-stable, broad-spectrum a...
We're developing Vipax, the world's first porta...
Theravance Biopharma is a diversified biopharmaceutical company with the core purp...
Theravance Biopharma is a diversified biopharma...
Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical c...
Corbus Pharmaceuticals Holdings, Inc. is a Phas...
ChemoCentryx is a biopharmaceutical company focused exclusively on discovering, de...
ChemoCentryx is a biopharmaceutical company foc...
Equillium is a biotechnology company leveraging deep understanding of immunobiolog...
Equillium is a biotechnology company leveraging...
Midatech is an international specialty pharmaceutical company focused on the devel...
Midatech is an international specialty pharmace...
Join the National Investor Network and get the latest information with your interests in mind.